Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb
Novo Nordisk shares tumbled Tuesday after the Danish pharmaceutical giant released updated financial guidance that, while improved from…
Novo Nordisk’s Defining Moment: Can a Pill Outweigh a Pipeline Setback?
The arithmetic of Novo Nordisk’s share price has become uncomfortably simple. At Monday’s close of 40.83 euros, the…
Novo Nordisk’s Pill Strategy Gets a Double Boost – EU Nod and Analyst Upgrade – Yet the Growth S
Novo Nordisk shares have recouped more than 40% from their early-March low, but the stock still sits nearly…
Wegovy Pill Wins EU Approval, Yet Novo Nordisk’s Rally Faces a Jittery Wait for FDA and Earnings
The European Commission has handed Novo Nordisk a clear edge in the race to dominate the oral weight?loss…
Novo Nordisk’s Oral Wegovy Clears EU Hurdle, Putting a Pricier Pill Against a Pricing Squeeze
Novo Nordisk has secured European approval for the first oral GLP-1 weight?loss tablet, a milestone that hands the…
Novo Nordisk Leverages Implant Tech, Oral Pill, and Aggressive Buyback to Counter Eli Lilly’s Moment
The competitive heat from Eli Lilly is forcing Novo Nordisk onto the front foot. The US rival’s tirzepatide…
Novo Nordisk Pushes on Two Fronts: Pill Adoption Surges as Implant Partnership Takes Shape
The Danish pharma giant is accelerating its assault on the obesity market from two distinct angles, pairing a…
Novo Nordisk’s Pill Lands in the UK With 70,000 Waiting as Medicare Push Opens a New US Front
Novo Nordisk is firing on two growth cylinders. The Danish pharma giant has just launched its oral Wegovy…
Oral Wegovy’s UK Rollout Puts Novo Nordisk’s Pivot to the Pill to the Test
Novo Nordisk’s long-anticipated shift from injection to tablet enters its most public phase this week, with the oral…
Novo Nordisk’s Pill and Medicare Double Act Fails to Silence Analyst Doubts
A dual catalyst – the UK launch of an oral version of Wegovy and a fresh US Medicare…
Novo Nordisk’s Pill Gamble: How Oral Wegovy Could Reshape the Obesity Market
The obesity drug arena is undergoing a fundamental recalibration. Volume is exploding, but pricing power is eroding. At…
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
By Maggie Fick and Andrew Silver BRUSSELS, June 24 (Reuters) – Eli Lilly’s orforglipron type-2 diabetes and obesity…